McGill Research + Innovation’s Post

Oak Ridge partnership supports next generation cancer treatment research! EM's Oak Ridge Office and contractor Isotek are leading an effort to eliminate the nation’s inventory of uranium-233 from storage at Oak Ridge National Laboratory. An agreement with TerraPower is allowing Isotek to extract thorium-229, an extremely rare isotope, from the material before it is processed and disposed of. Then, TerraPower uses that material to recover actinium-225, a medical isotope behind a promising form of cancer treatment called targeted alpha therapy. TerraPower recently announced that it's now producing the isotopes at commercial scale. That means more access and availability for clinical trials and treatments across the globe! #nuclearmedicine #cancerresearch Full story: https://lnkd.in/e-DN_QgK

📢 #Ariceum is pleased to announce that it presented outstanding data on its proprietary radiolabelled peptide SS0110 (#satoreotide) in a Top-Rated Oral Presentation at European Association of Nuclear Medicine (EANM) Annual Conference. ²²⁵Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer (#SCLC).   Highlights: 🔎 Satoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used 💡 100% survival with a single dose of 30 kBq ²²⁵Ac-satoreotide but not with ²²⁵Ac-DOTA-TATE   Learn more about Ariceum's presentation and ²²⁵Ac-Satoreotide, the first antagonist labelled with ²²⁵Ac to enter clinical development, in the press release linked in the comments 👇 #EANM #EANM24 #EANM2024 #biotech #oncology #lifesciences #oncology #cancer

📢 Exciting news! The latest results from our #PHERGain trial, which investigated the optimal [18F]FDG PET/CT cutoff point for predicting pathologic complete response (pCR) in HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab and pertuzumab, have been published in The Journal of Nuclear Medicine - JNM. Our study shows that an optimized ΔSUVmax cutoff point of at least 77% significantly improved the pCR rate to 59.5%, exceeding the 37.9% achieved with the original cutoff point of 40%. Although the higher cutoff point results in a higher pCR rate with trastuzumab and pertuzumab alone, the original cutoff point allows a higher proportion of patients to avoid chemotherapy (30.2% vs. 15.4%). Read the full article here: https://lnkd.in/d2sWF4qm #BreastCancerResearch #Innovation #Oncology #Research

🌟 SEPTEMBER: Prostate Cancer Awareness Month🌟 It is time to spotlight the importance of early detection, advanced treatment options, and ongoing research. Prostate cancer remains one of the most common cancers in men, but with timely screening and innovative medical approaches, we can make a significant impact. Nuclear medicine plays a crucial role in the diagnosis, staging, and treatment of prostate cancer. From advanced PET/CT imaging to targeted radionuclide therapies, nuclear medicine is at the forefront of personalized care, offering precision that can lead to better outcomes. Let’s raise awareness, support research, and encourage the men in our lives to take proactive steps for their health. #ProstateCancerAwareness #NuclearMedicine #MensHealth #EarlyDetection #ProstateCancer

#NTSR1 was found to be highly expressed across multiple types of cancers, especially in #head and neck and #colorectal cancer. #FL-091 displayed enhanced binding affinity to NTST1 and antagonist activity compared to 3BP-227. In addition, #177Lu-FL-091 demonstrated improved in vivo biodistribution profile vs. 177Lu-3BP-227 with increased tumor uptake and normal tissue clearance rate. In particular, 177Lu-FL-091 showed promising in vivo efficacy in different #xenograft models , with more favorable anti-tumor activity against 177Lu-3BP-227 at the same dose level. Collectively the results suggest 177Lu-FL-091 as a promising radioligand candidate for the treatment of #NTSR1 positive cancers. #biomarker #imaging #radioligand #pancreas #innovation #science #breastcancer #oncology #nucleartherapy

What is the potential role of nuclear localization of Glyoxalase 2 as a survival factor in human MCF7 breast cancer cells? Join Brenda Romaldi, Marche Polytechnic University at #RedoxMedicine2024 where she will present a poster developing this topic. The study that will be presented investigates the nuclear localization of glyoxalase 2 and its role as a survival factor in breast cancer cells. It enhances understanding of the molecular mechanisms underlying cancer cell survival, offering potential targets for therapeutic intervention. Join us on June 27-28, 2024 at Fondation Biermans-Lapôtre, Paris! 🔗 Accepted Posters: https://lnkd.in/gWjW7R7G 🌐 Learn More: https://lnkd.in/dkNzFQZU. #RedoxMedicieSociety #RedoxMedicine2024 #biomarkers #redoxbiology #redox #antioxidants #innovation #oxidativestress #RedoxResearch

Theranostic radionuclides such as radium-223 and lutetium-177 may be more cost-effective for treating metastatic castration-resistant prostate cancer than traditional therapies because of longer survival and better quality of life, according to a study prepared for presentation at the Radiological Society of North America's annual meeting. "Policymakers and health care providers should consider these findings to optimize treatment strategies and improve patient outcomes in mPCa [metastatic prostate cancer] care," researchers said

𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗻𝗲𝘄𝘀 𝗶𝗻 𝗽𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵! #RECIP 1.0 after 2 cycles of 177Lu-PSMA-617 is associated with progression-free survival in mCRPC! Median progression-free survival in RECIP-PD was only 2.5 months compared to 7.2 months in patients with RECIP-nonPD. 𝗞𝗲𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁: PSMA-PET/CT evaluated by RECIP 1.0 can be used in earlier stages of prostate cancer to evaluate drug efficacy and predict progression-free survival. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻: Visual RECIP 1.0 can be calculated by physicians to identify tumor progression on PSMA-PET/CT, ready for clinical practice. 🔗 Check out the article to learn more: https://lnkd.in/eFm_wRz7 #JNM #PSMA The Journal of Nuclear Medicine - JNM Andrei Gafita, Loïc Djaïleb, Matthias Eiber, Jeremie Calais, Ken Herrmann, Andrea Farolfi

resilience

Our paper is out linking PDIs (protein disulphide isomerases) with nuclear biomechanics and breast cancer cell invasion. Moreover, it is very interesting that SUN2 (a core LINC complex component) oligomerisation follows the “form follows function” principle. https://lnkd.in/gdmhB3Nk